Brainstorm Cell | 8-K: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.19, beating the estimate of USD -0.37.

EBIT: As of FY2025 Q3, the actual value is USD -1.988 M.

Financial Results for the Third Quarter Ended September 30, 2025

Cash and Cash Equivalents

• Cash, cash equivalents, and restricted cash were approximately $0.23 million as of September 30, 2025.

Research and Development Expenditures

• Research and development expenditures, net, for the quarter ended September 30, 2025 were $0.9 million, compared to $1 million for the quarter ended September 30, 2024.

General and Administrative Expenses

• General and administrative expenses for the quarter ended September 30, 2025 were approximately $1.1 million, compared to approximately $2.0 million for the quarter ended September 30, 2024.

Net Loss

• Net loss for the quarter ended September 30, 2025, was approximately $2.1 million, as compared to a net loss of approximately $2.7 million for the quarter ended September 30, 2024.

Net Loss Per Share

• Net loss per share for the three months ended September 30, 2025, and 2024 was $0.19 and $0.51, respectively.

Outlook / Guidance

• BrainStorm Cell Therapeutics Inc. is advancing key pre-initiation activities for the Phase 3b clinical trial of NurOwn, with U.S. FDA clearance secured. The trial is expected to enroll approximately 200 participants at leading ALS centers.
• The company is committed to working with the ALS community and believes that, if approved, NurOwn will be a valuable therapeutic approach that would slow disease progression and improve quality of life for people afflicted with ALS.